Sibrotuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | FAP |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| (what is this?) (verify) | |
Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP
In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.